The role of norepinephrine in the pathophysiology of cognitive disorders: Potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease
The role of norepinephrine in the pathophysiology of cognitive disorders: Potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease
复制标题
DOI：
10.1016/s0006-3223(99)00232-2
复制
发表时间：
1999-11-01
影响因子：
10.6
通讯作者：
Davis, KL
中科院分区：
文献类型：
--
作者：
Friedman, JI;Adler, DN;Davis, KL
去甲肾上腺素能神经传递在正常认知功能中的作用已经得到了广泛的研究，但去甲肾上腺素能神经传递功能在精神分裂症和阿尔茨海默病相关认知障碍中的作用还没有被深入研究。非典型抗精神病药物治疗精神分裂症认知障碍的能力有限，类胆碱能药物治疗阿尔茨海默病认知障碍的能力有限，可能与包括去甲肾上腺素能功能障碍在内的多种神经递质异常的影响有关，这些治疗方法无法解决这些问题。在精神分裂症和阿尔茨海默病中，去甲肾上腺素能功能障碍与多巴胺功能障碍和乙酰胆碱功能障碍并存的证据支持将去甲肾上腺素能药物分别与神经镇静剂和胆碱酯酶抑制剂联合使用来加强认知障碍的治疗。考虑到动物和人类研究的结果，α-2a激动剂似乎是达到这一目的的最佳选择。(C)1999年生物精神病学学会。
The role of noradrenergic neurotransmission in normal cognitive functions has been extensively investigated however, the involvement of noradrenergic functions in the cognitive impairment associated with schizophrenia and Alzheimer's disease has not been as intensively considered. The limited ability of atypical antipsychotics to treat the cognitive impairment of schizophrenia, and cholinomimetics to treat the cognitive impairment of Alzheimer's disease, may be related to the influence of a multiplicity of neurotransmitter abnormalities including noradrenergic dysfunction, which these treatments do not address. The evidence of noradrenergic dysfunction occurring concomitantly with dopamine dysfunction in schizophrenia and acetylcholine dysfunction in Alzheimer's disease supports therapeutic approaches using noradrenergic drugs in combination with neuroleptics and cholinesterase inhibitors, respectively, to enhance the treatment of cognitive impairment. Given the results of animal and human studies, it appears that alpha-2A agonists may be the optimal choice for this purpose. (C) 1999 Society of Biological Psychiatry.